Kazuyoshi Suenari

Dr. Kazuyoshi Suenari


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2012 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
KSKazuyoshi Suenari
Kazuyoshi Suenari
YNYukiko Nakano
Yukiko Nakano
YHYukoh Hirai
Yukoh Hirai
HOHiroshi Ogi
Hiroshi Ogi
NONoboru Oda
Noboru Oda
YKYasuki Kihara
Yasuki Kihara

1 January 2007 in Hypertension Research
Verified
Journal Article
Closed access
PDF file
MMMiwa Miyoshi
Miwa Miyoshi
YNYukiko Nakano
Yukiko Nakano
TSTakemasa Sakaguchi
Takemasa Sakaguchi
HOHiroshi Ogi
Hiroshi Ogi
NONoboru Oda
Noboru Oda
KCKazuaki Chayama
Kazuaki Chayama
Paraoxonase-1 (PON-1) is a high-density lipoprotein (HDL)−associated enzyme that hydrolyzes oxidized phospholipids, thereby preventing the oxidative modification of low-density lipoproteins (LDL). A high-fat diet reduces PON-1 activity, enhancing LDL oxidation. Thus, PON-1 is a candidate for anti-atherogenic gene therapy. In the present study, we investigated the effect of local PON-1 overexpression on the development of atherosclerotic lesions using the Sendai virus–mediated transgenic technique. One-month-old rabbits (n=11) were fed a high-fat diet for 8 weeks and then subjected to balloon injury of the common iliac artery and simultaneous infection with a Sendai virus vector containing the PON-1 gene (n=7) or enhanced green fluorescence protein (EGFP) gene as a control (n=4). The arteries were examined 7–10 days after the operation. Local overexpression of PON-1 almost completely eliminated the immunohistochemical signals of the lectin-like oxidized LDL receptor-1 (LOX-1), thereby inhibiting macrophage accumulation, intimal thickening (by 63% compared with control), or atherosclerotic plaque formation in the vascular lumen (by 87.5%). Decreased levels of oxidative stress in the PON-1−treated arteries were confirmed by 4-hydroxy-2-nonenal (HNE) staining. Local overexpression of PON-1 in the arteries attenuated oxidative stress, thereby inhibiting the atherosclerotic process. Delivery of the PON-1 gene may be a possible therapeutic strategy for preventing atherosclerosis.

1 January 2008 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KSKazuyoshi Suenari
Kazuyoshi Suenari
NSNobuo Shiode
Nobuo Shiode
KSKinya Shirota
Kinya Shirota
HIHiroshige Ishii
Hiroshige Ishii
KGKenji Goto
Kenji Goto
KCKazuaki Chayama
Kazuaki Chayama
Objective In patients with acute myocardial infarction (AMI), angiographic slow/no-flow during percutaneous coronary intervention (PCI) may lead to unfavorable outcomes. The aim of our study was to investigate the predictors and long-term prognosis of AMI patients with angiographic slow/no-flow. Methods We evaluated 228 consecutive AMI patients with either normal flow (Thrombolysis in Myocardial Infarction [TIMI] flow grade 3)(n=192) or slow/no-flow (≤TIMI-2)(n=36) based on cineangiograms performed during PCI. Results Multivariable analysis demonstrated that a long lesion (≥10 mm)(odds ratio [OR], 3.514; 95% confidence interval [CI], 1.505-8.206; p=0.004) and acute hyperglycemia (≥180 mg/dl)(OR, 3.011; 95% CI, 1.211-7.485; p=0.018) were significant and independent predictors of angiographic slow/no-flow. Further, we found that there was a high correlation (89%) for predicting angiographic slow/no-flow when the optimal cut-off values of lesion length (10.45 mm) and blood glucose levels on admission (187.5 mg/dl) were combined as identified by analysis of the receiver operating characteristic curves. One-year mortality and incidence of major adverse cardiac and cerebrovascular events (MACCE) were significantly higher in the slow/no-flow group than that in the normal flow group. Angiographic slow/no-flow was independently predictive of MACCE (hazard ratio [HR], 3.642; 95% CI, 1.208-10.980; p=0.022) and cardiac death (HR, 5.287; 95% CI, 1.155-24.204; p=0.032). Conclusions Lesion length and blood glucose level on admission can be used to stratify AMI patients into a lower or higher risk for angiographic slow/no-flow before optimal coronary intervention. In addition, angiographic slow/no-flow predicts an adverse outcome in AMI patients.

1 January 2016 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
YNYukiko Nakano
Yukiko Nakano
HOHidenori Ochi
Hidenori Ochi
YOYuko Onohara
Yuko Onohara
MTMasaaki Toshishige
Masaaki Toshishige
TTTakehito Tokuyama
Takehito Tokuyama
YKYasuki Kihara
Yasuki Kihara
Background—: Risk stratification of Brugada syndrome (BrS) remains controversial and the majority of patients with BrS have no genetic explanation. We investigated relationships between genotypes of 3 single-nucleotide polymorphisms reported in a recent genome-wide association study and BrS phenotypes. Methods and Results—: SCN10A (rs10428132), SCN5A (rs11708996), and downstream from HEY2 (rs9388451) single-nucleotide polymorphisms were genotyped and compared between 95 Japanese patients with BrS and 1978 controls. Relationships between the single-nucleotide polymorphisms and clinical characteristics, 12-lead ECG findings, signal-averaged ECG findings, and electrophysiological parameters were also examined in patients with BrS. Both rs10428132 and rs9388451 were significantly associated with BrS ( P =2.7×10 −14 ; odds ratio, 3.0; P =9.2×10 −4 ; odds ratio, 1.7, respectively). Interestingly, the HEY2 risk allele C was less frequent in BrS patients with ventricular fibrillation than in those without (59% versus 74%; P =4.1×10 −2 ; odds ratio, 0.5). A significant linear correlation was found between HEY2 genotypes and QTc interval (CC: 422±27 ms; CT: 408±21 ms; and TT: 381±27 ms; P = 4.0×10 −4 ). The HEY2 mRNA expression level in the right ventricular specimens from patients with BrS (n=20) was significantly lower in patients with CC genotype than the other genotypes ( P =0.04). Additionally, during 63±28 months follow-up periods after implantable cardioverter defibrillator implantation (n=90), Kaplan–Meier event-free survival curves revealed that the cumulative rate of ventricular fibrillation events was significantly lower in cases with HEY2 CC genotype ( P =0.04). Conclusions—: Our findings suggest that HEY2 CC genotype may be a favorable prognostic marker for BrS, protectively acting to prevent ventricular fibrillation presumably by regulating the repolarization current.

16 March 2021 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
KSKazuki Suruga
Kazuki Suruga
KSKazuyoshi Suenari
Kazuyoshi Suenari
TNTakayuki Nakano
Takayuki Nakano
HTHajime Takemoto
Hajime Takemoto
YHYuu Hashimoto
Yuu Hashimoto
HIHiroshi Ito
Hiroshi Ito

28 December 2013 in Echocardiography
Verified
Journal Article
Closed access
PDF file
NYNaoyasu Yoshida
Naoyasu Yoshida
MOMitsunori Okamoto
Mitsunori Okamoto
HHHidekazu Hirao
Hidekazu Hirao
KSKazuyoshi Suenari
Kazuyoshi Suenari
KNKiyomi Nanba
Kiyomi Nanba
HUHironori Ueda
Hironori Ueda